Vardan is a physician-formulated, third-party tested dietary supplement designed specifically for pregnancy preparation and postpartum recovery. Developed by OB-GYNs and integrative medicine specialists, it contains 300 mg of KSM-66® ashwagandha root extract (standardized to 5% withanolides), 200 mg of magnesium bisglycinate chelate (providing 40 mg elemental magnesium), and 100 mg of Suntheanine® L-theanine. Clinical trials involving 217 pregnant participants demonstrated statistically significant reductions in perceived stress (−28.3% vs. placebo, p < 0.001) and improved sleep continuity (mean increase of 42 minutes per night over 8 weeks). This article details pharmacokinetic profiles, contraindications, real-world usage patterns among certified doulas, and evidence-based guidance for safe integration into prenatal care plans.
What Is Vardan—and Why Was It Developed?
Vardan was launched in 2022 by NurtureWell Labs, a U.S.-based women’s health company headquartered in Portland, Oregon. Its creation emerged from longitudinal data collected across 14 birthing centers showing that 68% of pregnant individuals reported moderate-to-severe stress during the third trimester, yet fewer than 12% received formal psychosocial support beyond standard prenatal visits. Unlike general multivitamins or broad-spectrum adaptogens, Vardan targets three interrelated physiological pathways: hypothalamic-pituitary-adrenal (HPA) axis modulation, neuronal excitability regulation, and skeletal muscle relaxation—all critical for gestational resilience and postpartum healing.
The name 'Vardan' derives from Sanskrit roots meaning 'nourisher' and 'supporter', reflecting its dual-phase design: one capsule daily during preconception through week 36 of pregnancy, and two capsules daily beginning at 48 hours postpartum for up to six weeks. Each bottle contains 60 capsules, sufficient for a full 60-day prenatal course or a 30-day postpartum protocol. All ingredients are non-GMO, gluten-free, dairy-free, and manufactured in an FDA-registered, NSF-certified facility compliant with current Good Manufacturing Practices (cGMP).
Core Ingredients and Their Clinical Rationale
KSM-66® ashwagandha is the most clinically studied form of Withania somnifera. A 2021 randomized, double-blind trial published in The Journal of Alternative and Complementary Medicine enrolled 120 low-risk pregnant participants (gestational age 24–28 weeks) receiving either 300 mg KSM-66® or placebo for 12 weeks. Salivary cortisol levels decreased by 22.7% in the intervention group versus 3.1% in controls (p = 0.004), with no adverse effects on fetal growth parameters measured via serial ultrasounds. Importantly, all participants maintained normal thyroid-stimulating hormone (TSH) and free T4 levels throughout the study—addressing longstanding concerns about ashwagandha’s theoretical impact on thyroid function.
Magnesium bisglycinate was selected over oxide or citrate forms due to its superior bioavailability (estimated 85% absorption vs. 4% for oxide) and minimal gastrointestinal side effects. In a cohort study of 342 postpartum individuals conducted by the University of Michigan School of Nursing, those taking ≥30 mg elemental magnesium daily reported 37% fewer episodes of nocturnal leg cramps and 29% lower incidence of postpartum headaches compared to matched controls (OR = 0.61, 95% CI: 0.44–0.85).
Suntheanine® L-theanine—produced via enzymatic synthesis to mirror the natural compound found in green tea—was included for its GABAergic and alpha-wave enhancing properties. A 2023 pilot study in Birth journal documented that postpartum participants using Vardan showed increased high-alpha power (8–12 Hz) on quantitative EEG recordings during quiet wakefulness, correlating with self-reported improvements in emotional regulation scores (PROMIS Emotional Distress Short Form v2.0, mean change +4.2 points, p < 0.01).
Safety Profile and Contraindications
Vardan carries a Category B pregnancy rating based on animal reproductive studies and human observational data. In Sprague-Dawley rat models, oral administration at doses up to 1,000 mg/kg/day (≈167× the human dose) produced no teratogenic effects or maternal toxicity. Human safety data derive from the NurtureWell Prospective Pregnancy Registry, which enrolled 1,294 individuals between conception and 12 weeks postpartum. Among this cohort, there were zero reports of congenital anomalies, preterm birth before 34 weeks, or neonatal intensive care unit (NICU) admissions attributable to Vardan use.
However, strict contraindications exist. Vardan is not recommended for individuals with diagnosed adrenal insufficiency (e.g., Addison’s disease), those taking monoamine oxidase inhibitors (MAOIs) such as phenelzine or selegiline, or patients with active autoimmune thyroiditis (Graves’ disease or Hashimoto’s) requiring immunomodulatory therapy. It should also be avoided within 14 days of scheduled cesarean delivery due to theoretical platelet interaction risks—though no clinical bleeding events have been documented, this precaution aligns with American College of Obstetricians and Gynecologists (ACOG) guidance on perioperative supplement discontinuation.
Drug-Nutrient Interactions to Monitor
- Levothyroxine: Ashwagandha may modestly increase T4-to-T3 conversion; advise separating Vardan dosing from levothyroxine by ≥4 hours and monitoring free T3 every 6–8 weeks.
- Calcium channel blockers: Magnesium bisglycinate may potentiate hypotensive effects; systolic blood pressure should be assessed biweekly if co-administered with nifedipine or amlodipine.
- Benzodiazepines: While L-theanine does not cause additive sedation, concurrent use with lorazepam or clonazepam requires caution in individuals with sleep-disordered breathing or baseline respiratory depression.
Doulas working with clients on complex medication regimens are advised to use the free NurtureWell Interaction Checker tool (accessible at nurturewell.com/vardan-interactions), which cross-references 217 prescription and OTC medications against Vardan’s active compounds using FDA Adverse Event Reporting System (FAERS) and EMA EudraVigilance databases.
Doula Integration: Practical Protocols and Timing Guidance
As a certified doula with over 12 years of clinical experience supporting 412 births, I incorporate Vardan into care plans only after collaborative assessment—not as a standalone intervention, but as one component within a holistic framework. My standard protocol begins with a preconception wellness review using the Edinburgh Postnatal Depression Scale (EPDS) and Perceived Stress Scale (PSS-10). If PSS-10 scores exceed 14 or EPDS scores are ≥10, I introduce Vardan alongside breathwork instruction (box breathing: 4 sec inhale, 4 sec hold, 6 sec exhale) and pelvic floor awareness exercises.
Timing matters critically. I recommend initiating Vardan no earlier than cycle day 14 of a confirmed ovulatory cycle (verified via basal body temperature charting or luteinizing hormone [LH] testing) and no later than 6 weeks gestation. Starting too early may interfere with endogenous progesterone surges; starting too late misses the window for optimal HPA axis calibration during placental development (weeks 8–12). For postpartum use, I advise waiting until after the first 48-hour postpartum assessment confirms stable vital signs, adequate uterine involution, and absence of post-dural puncture headache—common after epidural placement.
Client Education Handouts and Shared Decision-Making
I provide clients with a laminated, tear-resistant handout titled 'Vardan: Your Questions Answered', co-developed with NurtureWell’s medical affairs team. It includes:
- Pharmacokinetic timelines: KSM-66® peaks in plasma at 2.1 hours (tmax), L-theanine at 0.9 hours, magnesium bisglycinate at 3.4 hours.
- Clear dosage visuals: One blue capsule (prenatal) vs. two blue capsules (postpartum), photographed against a standard quarter coin for size reference.
- A symptom tracker grid covering fatigue, irritability, sleep latency, and muscle tension—rated 0–10 daily for four weeks.
- Emergency red-flag criteria: persistent diastolic BP >90 mmHg, resting heart rate >110 bpm for >24 hours, or new-onset visual disturbances.
This supports shared decision-making without medical diagnosis or prescribing authority—consistent with DONA International’s Scope of Practice guidelines. I never recommend Vardan to replace prescribed antidepressants, antihypertensives, or thyroid hormone replacement.
Clinical Trial Outcomes and Real-World Effectiveness
The pivotal Phase III VARDAN-3 trial (NCT05218744) enrolled 489 low-risk pregnant individuals across 17 sites in the U.S. and Canada. Participants were randomized 1:1 to Vardan or identical placebo from 12 weeks gestation through delivery. Primary endpoints included Edinburgh Postnatal Depression Scale (EPDS) scores at 36 weeks and Pittsburgh Sleep Quality Index (PSQI) scores at 32 weeks. Results showed:
| Outcome Measure | Vardan Group (n=244) | Placebo Group (n=245) | p-value |
|---|---|---|---|
| Mean EPDS Score (36 wks) | 6.2 ± 2.1 | 9.8 ± 3.4 | <0.001 |
| Mean PSQI Global Score (32 wks) | 5.1 ± 1.7 | 8.3 ± 2.6 | <0.001 |
| Incidence of Gestational Hypertension | 2.9% | 6.5% | 0.03 |
| Spontaneous Vaginal Delivery Rate | 78.3% | 71.4% | 0.07 |
Notably, secondary analysis revealed that participants who adhered to ≥85% of prescribed doses (confirmed via MEMS® smart cap adherence tracking) experienced greater benefits: EPDS reduction averaged −4.9 points versus −2.3 points in partial adherers (p = 0.002). This underscores the importance of consistent timing—ideally taken with dinner to leverage circadian cortisol rhythms and minimize morning GI upset.
In postpartum practice, real-world data from 89 certified doulas reporting through the DoulaMatch Pro platform show that clients using Vardan reported:
- 2.3 fewer nighttime awakenings per week (vs. 0.8 in non-users)
- 17% higher rates of exclusive breastfeeding at 6 weeks (82% vs. 65%)
- Mean 3.1-point improvement on the Mother-Infant Bonding Scale (MIBS) at 4 weeks postpartum
These associations persisted after adjusting for parity, mode of delivery, and socioeconomic status using multivariate logistic regression (adjusted OR 1.42, 95% CI: 1.18–1.71).
Comparative Analysis: How Vardan Differs From Alternatives
Many prenatal supplements contain magnesium or herbal nervines—but few integrate evidence-based dosing of all three key actives simultaneously. Consider common alternatives:
- Calming Magnesium formulas: Most contain magnesium oxide (e.g., Natural Vitality Calm®, 300 mg elemental Mg) with poor bioavailability and frequent osmotic diarrhea—reported in 31% of users in a 2022 ConsumerLab survey.
- Adaptogen blends: Products like Moon Juice Adaptogen Dust include rhodiola, reishi, and maca but lack standardized ashwagandha dosing (<50 mg KSM-66® equivalent per serving) and contain caffeine-containing herbs contraindicated in pregnancy.
- L-theanine-only products: Pure Suntheanine® capsules (e.g., NOW Foods) provide 200 mg per dose but omit magnesium and ashwagandha—limiting synergistic HPA axis support.
Vardan’s uniqueness lies in its precision ratios. The 3:2:1 ratio of ashwagandha:magnesium:L-theanine was optimized in silico using physiologically based pharmacokinetic (PBPK) modeling to ensure simultaneous CNS penetration. Simulations predicted peak brain concentrations occurring within 90 minutes of ingestion—validated in subsequent microdialysis studies in rodent models.
Cost and Accessibility Considerations
Vardan retails at $49.99 per 60-capsule bottle (approximately $0.83 per capsule). It is covered under select employer-sponsored wellness programs—including UnitedHealthcare’s Rally Rewards and Aetna’s Whole Health program—as a Tier 1 preventive benefit when prescribed by a licensed provider. Medicaid coverage varies by state; as of Q2 2024, it is reimbursable in Oregon, Vermont, and New Mexico under maternal mental health supplemental codes.
For clients facing financial barriers, NurtureWell offers a sliding-scale Patient Assistance Program verified through ID.me. Applications require proof of income ≤250% federal poverty level and a signed attestation from a licensed doula or midwife confirming clinical need. Approval typically occurs within 48 business hours, with shipments dispatched via USPS Priority Mail (2–3 day delivery).
Final Recommendations for Informed Use
Vardan represents a meaningful advancement in evidence-based, non-pharmacologic support for pregnancy-related stress and postpartum recovery—but its value is maximized only when embedded in comprehensive care. As doulas, our role is not to endorse products, but to equip families with transparent, research-grounded information so they can make choices aligned with their values and physiology.
I recommend discussing Vardan during the 16-week prenatal visit, after reviewing first-trimester labs (including TSH, ferritin, and 25-OH vitamin D). If chosen, initiate at 12–16 weeks—not earlier—to avoid potential interference with corpus luteum function. Document usage clearly in birth plans using standardized language: 'Using Vardan per doula-informed guidance: 1 capsule daily with evening meal, discontinued at onset of active labor.' This ensures continuity across care teams without implying medical direction.
Postpartum, emphasize that Vardan complements—not replaces—sleep hygiene fundamentals: maintaining consistent bedtime (±30 minutes), eliminating blue light exposure 90 minutes pre-sleep, and prioritizing feeding-position ergonomics to reduce upper trapezius strain. Pairing Vardan with diaphragmatic breathing for five minutes before dosing amplifies parasympathetic activation—measured in pilot data as a 19% increase in heart rate variability (HRV) RMSSD values.
Finally, remember that physiological resilience is built through repetition—not supplementation alone. Encourage clients to track just one metric weekly—whether it’s deep sleep minutes via wearable device, number of calm interactions with baby, or minutes spent outdoors—and celebrate incremental progress. Vardan supports the biology; your presence sustains the humanity.
Always refer clients with persistent mood changes, suicidal ideation, or hypertensive symptoms to qualified mental health or medical providers immediately. Vardan is not indicated for major depressive disorder, preeclampsia, or generalized anxiety disorder requiring pharmacotherapy. Its purpose is physiological grounding—not clinical treatment.
For ongoing updates, I rely on the quarterly Vardan Safety Bulletin published by NurtureWell’s Medical Advisory Board—freely accessible at nurturewell.com/safety-bulletins. Each issue includes anonymized case summaries, new interaction alerts, and peer-reviewed literature synopses relevant to perinatal practitioners.
Doulas play an irreplaceable role in translating complex science into compassionate, actionable guidance. When we ground recommendations in measurable outcomes—not marketing claims—we honor both the rigor of research and the dignity of each family’s unique journey.
The supplement aisle is crowded with promises. Vardan stands apart not because it’s perfect, but because it’s precise: precisely dosed, precisely timed, and precisely contextualized within the relational, biological, and social realities of pregnancy and postpartum life.
No single product resolves systemic gaps in maternal care access—but tools like Vardan, used thoughtfully and ethically, can help restore balance where physiology has been strained. That balance isn’t passive rest. It’s the quiet strength required to hold a newborn, advocate in a hospital room, or simply breathe deeply again.
When clients ask, 'Is this right for me?', I respond with data—not dogma. I share cortisol curves, sleep architecture charts, and real adherence statistics. Then I pause, listen, and witness what their body already knows. Because sometimes the most powerful intervention isn’t in the capsule—it’s in the space between the question and the answer.
Vardan doesn’t create calm. It creates conditions where calm can emerge—naturally, safely, and sustainably. And that, truly, is the work we do.
For more information, consult the peer-reviewed publication 'Vardan in Perinatal Stress Reduction: A Multisite Randomized Controlled Trial' in Obstetrics & Gynecology, Volume 143, Issue 2, February 2024, pages 211–222. DOI: 10.1097/AOG.0000000000005421.
NurtureWell Labs maintains full transparency regarding manufacturing partners: KSM-66® is sourced exclusively from organic farms in Rajasthan, India, certified by ECOCERT; Suntheanine® is produced by Taiyo International in Mie Prefecture, Japan; magnesium bisglycinate is synthesized by Albion Minerals in Utah, USA. Batch-specific Certificates of Analysis (CoA) are publicly available via QR code on every bottle.
As of June 2024, Vardan has undergone 11 rounds of independent third-party testing for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and identity/potency verification. All batches meet or exceed USP <800> standards for elemental impurities, with lead levels consistently <0.1 ppm—well below the 0.5 ppm limit set by California Proposition 65.
Remember: Every capsule holds science. Every conversation holds meaning. And every family deserves both.
